This revealed that KRAS mutation was associated with a significantly improved OCSS in endometroid carcinomas (p = 0.012, Figure 3C), while KRAS mutation status was not a prognostic factor in mucinous (Figure 3A) or serous carcinomas (Figure 3B). The gene discussed is KRAS; the disease is serous adenocarcinoma.